TP53, ATM Comutation Might Help Guide Lung-Cancer Immunotherapy TP53, ATM Comutation Might Help Guide Lung-Cancer Immunotherapy
In patients with non-small-cell lung cancer (NSCLC), the presence of tumor protein p53 (TP53) and ataxia-telangiectasia mutated (ATM) comutation might indicate better response to immune-checkpoint inhibitors (ICIs), according to Chinese researchers.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
More News: Allergy | Allergy & Immunology | Ataxia | Cancer | Cancer & Oncology | China Health | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer